Do GLP-1 Medicines Raise Macular Degeneration Risk? Why Crude Stats Flipped After Adjustment

Los Angeles patients on semaglutide or related GLP-1 medicines often ask whether those drugs hurt the macula. An AAO 2026 analysis of Epic Cosmos data shows why a simple “yes” from raw numbers can mislead.

Huge numbers, two different stories

Franklin Ye Ruan and colleagues examined more than 300 million patient records. About 15.4 million had GLP-1 receptor agonist exposure, 1.38 million had age-related macular degeneration (AMD), and 115,056 had both.

• Crude odds ratios suggested higher AMD odds with GLP-1 use: 1.68 for any AMD, 1.89 for dry AMD, and 1.53 for wet AMD.
• After Mantel-Haenszel adjustment for type 2 diabetes, the odds ratios reversed to 0.69 for any AMD and 0.62 for wet AMD.
• Adjustment for hypertension or hyperlipidemia produced a similar reversal.
• Body-mass-index adjustment attenuated the crude association to about 1.17; adjusting for age pushed crude-style odds higher (about 1.94).

In plain language, people who take GLP-1 drugs also tend to have the cardiometabolic problems that travel with AMD risk. Once those factors are accounted for, the apparent harm signal does not hold in this analysis. The authors called for more rigorous studies rather than prescribing changes based on unadjusted charts alone.

How this fits other GLP-1 eye headlines

Separate research has examined rare optic-nerve events and other retinal associations with GLP-1 medicines. Those stories are not the same as AMD risk. Each outcome needs its own adjusted analysis. The practical habit is the same: keep metabolic therapy decisions with the prescribing clinician, and keep macular surveillance with your eye doctor.

What we tell patients

• Do not stop a prescribed metabolic medicine because of an unadjusted headline.
• Keep dilated macular exams on the schedule your eye doctor recommends, especially after age 50 or with a family history of AMD.
• Retina disease care is referred out; we help with detection and coordination.

For more on aging eyes and systemic links written for patients, see bettereyesightatanyage.com.

Source: AAO: Association between GLP-1 receptor agonists and age-related macular degeneration explored (Medical Xpress / HealthDay (AAO 2026 presentation), 10/21/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.